Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
These therapies work at the cellular level to help maintain strength, energy, and healthy aging
Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
Multi-peptide stacks combining several compounds may cost more than single peptides
Weekly Regimen Guidelines Starting Conservative For those new to NAD+ research: Week 1-2: Start with 50-100mg twice weekly Week 3-4: Increase to 100-200mg twice weekly if tolerated well Maintenance: 100-250mg twice weekly Common Research Protocols Conservative Protocol: 50mg 2x/week = 100mg/week Moderate Protocol: 100mg 2x/week = 200mg/week Intensive Protocol: 150-250mg 2x/week = 300-500mg/week Administration Considerations Subcutaneous injection is the most common route Best absorbed when taken on an empty stomach Morning administration is generally preferred Some researchers report mild flushing or warmth at higher doses Calculating Your Dose Use the PeptIQ Reconstitution Calculator for precise measurements: Example calculation: Vial: 250mg NAD+ BAC water added: 5mL Concentration: 50mg/mL Desired dose: 100mg Volume to draw: 2mL (100mg 50mg/mL = 2mL) Storage Guidelines Reconstituted NAD+ should be refrigerated at 2-8C Use within 30 days of reconstitution Keep away from light to preserve potency Never freeze reconstituted solution Safety Considerations Always use sterile technique for reconstitution Use new needles for each draw Start low and increase gradually Monitor for any adverse responses This information is for research purposes only Conclusion Proper reconstitution and dosing are foundational to NAD+ research
The association between peptide levels and symptoms in FD and gastroparesis is summarized in Table 1
